MET and metabolic dysfunction-associated steatohepatitis: In line with hepatoprotective consequences of c-Met signaling in experimental NASH models, Pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma (PPARγ), which was shown to alleviate human steatohepatitis in clinical trials, acts through activation of c-Met (45).